PTEN and prostate carcinoma: Preclinical studies have also shown that co-inhibition of MEK and mTORC1 can significantly reduce tumor burden relative to monotherapy in a mouse model of prostate cancer driven by simultaneous heterozygous deletion of Nkx3.1 and Pten [256], and can inhibit cell growth and increase cytotoxicity in the castration-resistant CWR22Rv1 human prostate cancer cell line [272].